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Abstract
Platelets are essential elements of human blood. In addition to their normal role, platelets 
are involved in causing myocardial infarction, stroke and other thrombotic disorders. Platelet 
activation in vivo,	probably	involves	a	combination	of	agonists.	Garlic	has	beneficial	effects	
due to its ability to inhibit platelet aggregation and thromboxane formation. The aim of this 
work was to evaluate the ability of garlic extracts to inhibit platelet aggregation induced by 
different agonists and their mixtures in different donors.	Significant	differences	were	found	
in platelet aggregation in response to each agonist (P ≤ 0.05). The highest antiaggregatory 
effect was observed with arachidonic acid and the lowest effect with collagen-arachidonic 
acid mixture. Interaction effects between donor and agonist (or mixtures) were detected. 
The study showed the potential of aqueous garlic extracts to prevent platelet aggregation 
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Resumen
Las plaquetas son componentes esenciales de la sangre humana. Además de su rol 
normal, las plaquetas pueden estar involucradas en procesos que causan infarto de 
miocardio, apoplejía y otros trastornos trombóticos. La activación plaquetaria in vivo, invo-
lucra	una	combinación	de	agonistas.	El	ajo	posee	efectos	beneficiosos	debido	a	su	capacidad	
para inhibir la agregación plaquetaria y la formación de tromboxano. El objetivo fue evaluar 
la capacidad de extractos acuosos de ajo de inhibir la agregación plaquetaria inducida por 
diferentes agonistas y sus mezclas en diferentes donantes. Se encontraron diferencias signi-
ficativas	 en	 la	 agregación	plaquetaria	 en	 respuesta	 a	 cada	 agonista	 (P	≤ 0,05). El mayor 
efecto antiplaquetario se observó con el ácido araquidónico y el menor con la mezcla de 
colágeno y ácido araquidónico. Se evidenció efecto de interacción entre donante y agonista 
(o mezclas). El estudio muestra el potencial de los extractos acuosos de ajo para prevenir la 




Platelets are key elements of human blood. They play a central role in the process of 
thrombus formation as well as an important role in atherogenesis and the progression of 
atherosclerotic lesions (38). When platelets come in contact with damaged or disrupted 
endothelium, they are activated, changing their shape and releasing their granules content 
(33). A great number of agents, including adenosine diphosphate, epinephrine, collagen, 
thrombin, arachidonic acid, antigen-antibody complexes, serotonin and vasopresin, can 
induce platelet aggregation (11, 13). Collagen (C) is an extracellular matrix component, 
which directly binds to receptors that mediate platelet adhesion inducing activation and 
aggregation.	Two	receptors	are	involved	in	platelet	response	to	collagen;	integrin	α2 β1 acts 
adhering	platelets	to	collagen,	allowing	platelets	to	interact	with	the	lower	affinity	receptor	
glycoprotein VI, which is mainly responsible for platelet activation (37). Adenosine diphos-
phate	(APD),	 the	 first	known	 low	molecular	weight	platelet	aggregating	agent,	 is	a	weak	
platelet agonist. However, ADP plays an important role in platelet function given that, when 
released	 from	the	platelet	dense	granules,	 it	amplifies	 the	platelet	 responses	 induced	by	
others agonists (18). Arachidonic acid (AA) is considered a key component in haemostasis 
and thrombosis, since the release of AA can trigger platelet aggregation and prostaglandin 
synthesis. AA in reaction with cyclooxigenase is converted to thromboxane A2, a potent 
platelet agonist (9). Regarding epinephrine (E), the mechanism by which it induces platelet 
aggregation is unknown. In some tissues, such as the respiratory epithelium, the activation 
of the A2AR increases transcellular sodium and chloride cotransport (42). 
Several studies have approached platelet aggregation in response to in vitro stimulation 
of these agonists (9, 22, 37, 42). The fact that platelet aggregation in vivo involves a combi-
nation of agonists, is well known. Consequently, to evaluate various agonists simultaneously 
according to their way of action and their potential synergistic interaction, becomes useful 
(23). Platelet aggregation is performed to identify abnormal platelet function, to quantify 
platelet response, and to monitor platelet inhibition through therapeutic drug (29). As an 
alternative source of natural antithrombotic drugs, the pharmaceutical industry is currently 
considering garlic to develop better and safer drugs with lower and less side effects. However, 
the mechanisms by which aqueous garlic extract elicit their antiplatelet effect are not fully 
known. Garlic (Allium sativum L.) has been used for its antioxidant properties that prevent 
heart disease including atherosclerosis. Also reduces both plasma cholesterol level and 
blood pressure (12) and has been recognized as an antiplatelet agent that may contribute 
to the prevention of cardiovascular disease (34). Raw garlic and some of its preparation like 
aqueous extracts, garlic oil, aged garlic extract and garlic powder inhibit human platelet 
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the	most	abundant	compound,	representing	about	70%	of	the	overall	thiosulfinates	formed	
upon crushing garlic cloves (26). It is produced by the interaction of the nonprotein amino 
acid alliin (+S-allyl-L-cysteine sulfoxide), with the enzyme alliinase (alliin lyase, EC 4.4.1.4) 
(24).	Allicin	and	other	thiosulfinates	provide	nearly	all	the	antiplatelet	activity	of	raw	garlic	
homogenates in whole blood aggregometry (27). Variability in antiplatelet activity exerted 
by garlic cultivars belonging to different argentine ecophysiological groups using collagen 
as agonist has previously been described by our group (15). Perla INTA has the highest 
organosulfur levels, pungency and in vitro antiplatelet activity, being the most suitable 
garlic cultivar to obtain pharmacological products (15). In vitro platelet aggregation can 
be assayed with an electrical impedance aggregometer using different agonist and several 
donors.  Results may exhibit large variances both among and within platelet donors. Conse-
quently, it is desirable to use an experimental design with several agonists and donor’s in 
order to make their results comparable.
Therefore, this study was conducted to determine the in vitro antiplatelet activity of 
aqueous extract of Perla INTA cultivar induced by different agonists and their mixtures.
Materials and methods
Chemicals
All chemicals used were of analytical grade. Collagen (1mg mL-1) was purchased from 
Chrono-log Corp, adenosine diphosphate, arachidonic acid and epinephrine were obtained 
from Helena Laboratory (Beaumont, TX, USA). Stock solutions of each agonist were prepared 
in deionized water and mixed gently until completely dissolved at the following concentra-
tions: 10 µM ADP, 0,5 mM AA, epinephrine 50 µM. These solutions were stored at -20 °C, 
except for the collagen solution, which was stored at 4 °C. 
Preparation of aqueous garlic extracts
Fresh garlic bulbs of Perla INTA cultivar were chosen from the germplasm collection 
of INTA La Consulta, Mendoza, Argentina. The bulbs were peeled and blended for 1 min in 
deionized	water	(1:10	w/v).	The	aqueous	garlic	extract	was	collected,	filtered	and	kept	at	
room	temperature	for	15	min	to	allow	enzymatic	hydrolysis	of	the	flavor	precursors.	After	
that, the extracts were kept frozen at –80 °C.
Aqueous garlic extracts characterization
The characterization of Perla INTA aqueous garlic extract was carried out according 
to	their	flavor	precursor	levels,	thiosulfinates,	allicin	content,	and	pungency	as	previously	
described González et al. (2009). 
Platelet aggregation
Platelet aggregation was measured in vitro using a whole blood electrical impedance 
aggregometer (10). Blood was collected from nine non-smoker healthy donors (5 women, 4 
men), between 26-45 years old, who had no any previous disease and had not taken aspirin 
or any medication, and all had given informed consent. They also had abstained from eating 
Alliums or other known platelet-inhibitory food or beverages in the previous 2 weeks, for 
at least 7 days prior to venipuncture. A complete blood count, biochemical analysis and the 
clotting time was carried out following the Ivy method. Clotting times less than 9.5 minutes 
were considered normal. 
Blood samples were collected by venipuncture (Hematology Service, Central Hospital, 
Mendoza, Argentina) in tubes containing sodium citrate anticoagulant (3.8%, 1 vol of anti-
coagulant per 9 vol of blood). Afterward,blood samples were diluted in equal volume of 
TRIS buffered saline (TBS, pH 7.4) and vortexed. The diluted blood was maintained at room 
temperature during the experiment and used within 2 h of donation.
Aliquots of 1mL of blood/TBS were incubated for 3 min at 37 °C, then a dose of aqueous 
garlic extract was added and platelet aggregation was induced by the addition of different 
agonists or their mixtures. Changes in the impedance was recorded over 6 min. The change 
in impedance is proportional to the amount of platelet aggregation. All treatments were eval-
Garlic antiplatelet activity
49Revista de la Facultad de Ciencias Agrarias - UNCuyo | Tomo 53-1 - Año 2021
uated with each donor’s blood four times. In vitro antiplatelet activity (AAI) was expressed 
as percentage of inhibition of platelet aggregation, compared to control samples prepared 
in the same way but without adding aqueous garlic extract. The control is considered as 
100 % the aggregation or 0% the inhibition for each agonist. 
Table 1 shows agonists concentrations prepared as described Bordia et al. (1996); 
Soloviev et al. (1999); Rahman and Billington, (2000). Based on previous results a concen-
tration of 7 mg of aqueous garlic extract per mL of blood was chosen for platelet aggre-
gations reactions (15). This concentration is equivalent to a daily consumption of 1 clove 
(1.5 g of garlic for a person weighing 70 kg) (43).
Table 1. Concentration of stock solutions of each agonist and their mixtures.
Tabla 1. Concentración de las soluciones stock de cada agonista y sus mezclas.
Statistical analysis
Values were expressed as means ± SEM. Data were analyzed by analysis of variance (ANOVA) 
to	test	the	significant	differences.	Means	were	compared	using	Tukey’s	test.	The	results	were	
considered	significant	at	P	≤	0.05	unless	specified	otherwise.	Statistical	analysis	was	performed	





aggregation in the respective samples. A similar behavior was observed with epinephrine. 
Inhibition	percentage	 in	platelet	aggregation	showed	significant	differences	(figure	1,	
page 50) among different agonists as well as among their combinations. The inhibitory 
effect on platelet aggregation induced by collagen ranged between 22.5-100%. After adding 
collagen before aggregation onset, aggregation slopes showed a delay of about 60 s or more, 
then followed by a steady increase in aggregation. This delay was greater than control 
samples when garlic extract was added (data no shown). 
Antiplatelet aggregation, when AA was used, ranged between 75.7-100%. The aggre-
gation slopes showed a monophasic aggregation response to AA.
On the other hand, antiplatelet effects exerted by Perla INTA aqueous extract were 
studied by using different agonist mixtures. When a collagen–AA mixture was used as 
platelet agonist, antiplatelet activity ranged between 3.84-26%. In addition, in vitro Perla 
INTA aqueous extract suppressed platelet aggregation induced by collagen-epinephrine 
and ADP-epinephrine induced human platelet in a wide range, 10.23-48.48% and 20-80%, 
respectively.	Significant	synergistic	interaction	was	observed	with	collagen	in	combination	
with epinephrine, AA and ADP, and ADP in combination with epinephrine when added 












Collagen + Arachidonic acid
Collagen + Adenosine diphosphate
Collagen + Epinephrine
Adenosine diphosphate + Epinephrine
1 µg/mL + 0.5 mM
1 µg/mL + 10 µM
1 µg/mL + 50 µM
10 µM + 50 µM
a. Concentration per mL 
of whole blood.
b. Concentración por mL 
de sangre completa.
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Bars	represents	means	±	SD	(n=9).	Different	letters	indicate	significantly	different	according	to	Tukey	test	(P	≤	0.05).	ADP:	Adenosine	
diphosphate, E: Epinephrine, C: Collagen, AA: Arachidonic acid.
Barras	representan	valores	promedio	±	SD	(n=9).	Letras	distintas	indican	diferencias	significativas	según	test	Tukey	HSD	a	P	≤	0,05.	ADP:	
Adenosina difosfato, E: Epinefrina, C: Colágeno, AA: Ácido araquidónico.
Figure 1. In vitro inhibition of platelet aggregation exerted by Perla INTA aqueous extracts on platelet 
aggregation induced by different agonists and their mixtures. 
Figura 1. Inhibición de la agregación plaquetaria in vitro ejercida por extractos acuosos de Perla INTA sobre la 
agregación inducida por diferentes agonistas y sus mezclas.




































Values at right of bars indicate the concentrations of agonists used. ADP: Adenosine diphosphate, E: Epinephrine, C: Collagen, AA: Araquidonic acid.
Valores a la derecha de cada barra indican las concentraciones de agonistas usadas. ADP: Adenosina difosfato, E: Epinefrina, C: Colágeno, AA: 
Ácido araquidónico.
Figure 2. Aggregation platelet in vitro: synergistic effect exerted by different combinations of agonists. 
Figura 2. Agregación plaquetaria in vitro:	efecto	sinérgico	ejercido	por	diferentes	combinaciones	de	agonistas.	
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In general, the antiaggregatory effect showed by Perla INTA aqueous extract on platelet 
aggregation induced by paired of agonists were minor than antiaggregatory effects observed 
when	platelet	aggregation	was	induced	by	each	agonist	alone	(figure	1,	page	50).	
Taking into account average antiplatelet activity of all agonists and mixtures used, this 
biological activity varied between 18.51% ± 2.43 and 84.40% ± 2.15. The highest antiag-
gregatory effect was observed with AA and the lowest effect with collagen-AA mixture. 
ANOVA analysis revealed an interaction effect between donor and agonist (or mixtures) at 
P ≤ 0.05 (table 2). ANOVA analysis of donor, agonist and their interaction resulted in 15.2%, 
54.74% and 26.2 % of variation to the AAI in this study, respectively, indicating that agonist 
was the main factor determining AAI, and that donor and donor and agonist interaction, 
played	a	minor	role.	There	were	not	significant	differences	in	platelet	aggregation	inhibition	
response between women and men. 
Table 2. ANOVA table of in vitro antiplatelet activity variation due to donor, agonist, and 
their interaction.
Tabla 2. Tabla de ANOVA de la actividad antiplaquetaria in vitro por donador, agonista e 
interacción.
The	chemical	profile	of	the	main	organosulfur	compound	present	in	Perla	INTA	aqueous	
garlic extract is shown in table 3. Alliin was the most abundant ACSO, representing more 
than 70% of the total content of ACSOs, whereas isoallin content was nearly to 23% and 
methiin content represented less than 10%. Also, this cultivar showed high levels of thiosul-
finates,	allicin,	and	pungency.
Table 3. S-alk(en)yl-L-cysteine	sulfoxides	(ACSOs),	thiosulfinates,	allicin,	and	pungency	of	




Under pathological conditions, platelets may become more proadhesive/procoagulant, 
which leads platelets to adhere to an injured area, and to subsequently release a lot of active 
constituents inducing plug formation (16). For that reason, antiplatelet therapy is used as 
a strategy to prevent vascular thrombosis and vascular disorders. Several researchers have 
shown that garlic and their sub products have in vivo (1, 2, 8, 44) and in vitro (7, 28, 35) 
antiplatelet activity. These studies have involved the use of collagen, ADP, AA or epinephrine 





























Alliin 21.83 ± 1.33a
Methiin 1.53 ± 0.09 
Isoalliin 6.87 ± 0.32 
Total 30.22 ± 0.58
Total thiosulfinates (mM%g fw) 4.45 ± 0.1
Allicin (mg/g fw) 5.04 ±0.1 
Pungency (µMol/g fw) 79.86 ± 1.83
a Each value is the mean 
± SE (n = 5).
a Cada valor representa 
la media ± DS (n = 5). 
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as agonists, but not their combinations. In vivo, more than one agonist and different combi-
nations are involved in platelet activation. Therefore, the study of the antiplatelet effect of 
aqueous garlic extracts over platelet activity induced by different agonists and their combi-
nations was considered of great contribution to the understanding of the factors involved 
in this activity.  Two types of aggregation can be distinguished in vitro: primary aggregation 
that is reversible and occurs without the release reaction and secondary aggregation that 
is irreversible and is associated with the release reaction (36). The reversibility of platelet 
aggregation induced by each dose of agonists included in this study was assessed from the 
shape of aggregation tracings. A monophasic curve indicating irreversible aggregation was 
observed with all the agonist and the combinations evaluated. We found that when platelet 
aggregation was induced by ADP or epinephrine, the aggregation induced was lower than 
40% and 30% respectively. Similar results have been reported (6, 14, 25). Mammalian 
platelets vary widely in their responses to epinephrine, in part due to they can act via 
excitatory	α	receptors	and	inhibitory	β	receptors	(41).	Some	people	have	reduced	platelet	
responsiveness to epinephrine due to the lack of these receptors (39). This fact might 
explain the results obtained in our work. On the other hand, when these agonists were used 
in combination, a synergistic effect was observed. This was evidenced by higher responses 
than the expected for ADP or epinephrine alone. As it has been previously reported by other 
authors (19, 36).
Regarding collagen, we found that a concentration of 1 µg mL-1 induces of 100% of platelet 
aggregation in vitro. In addition, we observed that the concentration of Perla INTA aqueous 
garlic extract used inhibited the platelet aggregation induced by this agonist. Aqueous 
garlic extracts contain mainly allicin (26). Allicin easily go through cellular membranes and 
can	react	with	different	sulfhydryl	(SH)-containing	proteins	blocking	their	free	sulfhydryl	
residues (30). We propose that the antiplatelet effect of Perla INTA aqueous garlic extract is 
due,	at	least	partially,	to	the	inhibition	of	collagen	binding	to	specific	receptors	on	platelet	
surface. Consequently, platelet adhesion and platelet activation could be inhibited. This 
results are in agreement with Manaster et al (2009), who demonstrated that allicin inhibit 
agonist-induced washed platelet activation via inhibition of platelet signaling. According to 
Baghalian et al. (2005) the minimum allicin content to ensure pharmaceutical and economic 
viability of garlic should be 4.5 mg g-1 fw. The higher level of allicin present in this cultivar 
could be taken as an opportunity to elaborate pharmacological products based on its health-
benefit	quality.
A monophasic curve in response to a concentration of 0.5 µM of AA was obtained. 
Both aqueous and organic garlic extracts have been found to inhibit several steps of the 
AA-cascade in platelets (3). Moreover, garlic extracts inhibit incorporation of labeled AA 
into platelet phospolipids and inhibit AA-metabolizing enzymes in platelets (15). Ali (1995) 
showed that raw garlic inhibited cyclooxygenase activity non-competitively and irreversibly. 
Our	results	confirm	these	observations.	The	highest	antiaggregatory	effects	exerted	by	Perla	
INTA aqueous extract were observed when AA was used as agonist. 
Platelet aggregation in vivo probably involves a combination of agonists, being collagen 
more important at the beginning, thrombin becomes important later on, and with other 
agonists in different mixtures throughout (19). Platelets exhibit diverse responses, including 
shape change, aggregation, and secretion in response to a variety of agonists. These agonists 
differ in their intrinsic ability to produce the effects on physiological responses by platelet 
(14, 21). The degree of inhibition depends on the potential activity of each platelet agonist 
used in the present work. Perla INTA aqueous extract strongly inhibited platelet aggregation 
induced by a strong agonist like collagen and also by AA. However, the antiaggregatory effect 
was lower when the aggregation was induced by collagen together with AA. These results 
demonstrate the synergistic interaction exerted for the combination of agonists used. These 
results are in agreement with those reported by Razi et al (2005) and Huang and Detwiler 
(1981), who showed the potentiated response to platelet aggregation in combination of 
collagen and AA, and epinephrine. The synergism between the different platelet agonists 
increases platelet aggregations. Full platelet aggregation can also be induced by the simulta-
neous addition of subthreshold levels of platelet stimuli, which fail to induce platelet aggre-
gation on their own merit (21).
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Other	important	aspect	that	was	evaluated	was	the	influence	of	donor,	agonist	and	their	
interaction. Although, the analysis revealed an interaction effect between donor and agonist, 
the type of agonist was the main factor determining of in vitro antiplatelet activity. These 
results were consistent with previous reports that showed that the response of platelets to 
agonists has a large inter-individual variability within the population (31, 32).
Conclusion
This study reveals the potential antiaggregatory effect of Perla INTA aqueous garlic 
extract, when this activity is induced by different agonists and their mixtures. Several mech-
anisms	are	involved	in	this	inhibitory	effect,	and	they	include	the	modification	of	platelet	
membrane, a direct inhibitory effect on the AA metabolism and lipoxygenase enzyme and 
inhibition	 of	 calcium	 mobilization.	 The	 modification	 of	 platelet	 membrane	 inhibits	 the	
signaling pathway and consequently the platelet activation and platelet adhesion. When 
enzymes involved in several steps of AA-cascade are inhibited, endoperoxides interme-
diates are not converted to prostanglandins and thromboxane B2 which are potent platelet 
aggregators. Furthermore, a synergistic effect was evidenced. This aspect is important since 
the therapeutic effect of antiplatelet herbal drugs can be affected. However, the biochemical 
basis of these synergistic responses needs further exploration.
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